GlaxoSmithKline has appointed Luke Miels President, Global Pharmaceuticals, GSK. He will be responsible for a portfolio of medicines and vaccines with annual sales of more than £15 billion and operations in over 100 markets.
Luke will report to Emma Walmsley, who is currently CEO Designate and will become CEO of GSK in April 2017. His start date will be announced in due course.
Luke is currently Executive Vice President of AstraZeneca’s European business. Over the course of his career, Luke has built strategic partnerships between R&D and the relevant commercial organisations to develop superior portfolio and product franchises at AstraZeneca, Roche and Sanofi-Aventis. He is known for being competitive and strongly focussing on the interests of patients.
Emma Walmsley said that Luke brings a combination of excellent R&D insight and a strong track record of commercial execution, and added: “We are now entering a critical period of commercialization for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline. Luke will bring a strong new voice to the decisions and choices we will have to make for our Pharmaceuticals business. I am delighted he has agreed to join GSK and look forward to welcoming him to the executive team.”